#USA #New York #Class Action #Pomerantz #Ardent Health

Legal Action Initiated Against Ardent Health, Inc.

In a notable development for investors, Pomerantz LLP has announced the initiation of a class action lawsuit against Ardent Health, Inc. (NYSE: ARDT). This legal step, prompted by a significant decline in the company's stock price, has caught the attention of many shareholders who believe they were adversely affected by recent corporate mismanagement.

The class action centers around allegations of securities fraud and other unlawful business practices that may have been perpetrated by Ardent and certain executives. The filing serves as a call to action for those who purchased Ardent securities during the defined Class Period to potentially serve as Lead Plaintiffs in the case. Interested investors are urged to reach out to Pomerantz LLP for more details and support.

Background of the Case

The lawsuit comes on the heels of alarming news released by Ardent Health on November 12, 2025, which revealed a staggering $43 million decrease in their third-quarter revenues for the year. This loss stemmed from adjustments made regarding the collectability of accounts receivable after transitioning to a new revenue accounting system, specifically the Kodiak RCA net revenue platform. The company claimed this new system provided management with enhanced capabilities for assessing the collectability of accounts, although it has raised concerns among investors regarding its effectiveness and the timing of its implementation.

Ardent disclosed that their previous methodology allowed for a 180-day period before fully reserving accounts, which has now changed. After these adjustments, the company also reduced its EBITDA guidance for 2025 due to persistent industry pressures, indicating a cut from an expected range of $575 million-$625 million down to $530 million-$555 million, attributing it to increased costs and payer denials.

Further exacerbating the situation, Ardent reported a $54 million rise in professional liability reserves linked to settlements and ongoing litigation related to claims from 2019 to 2022 in New Mexico, alongside broader trends impacting the industry, particularly social inflation. Following the announcement of these grim financial realizations, Ardent’s stock price plummeted by 33.81%, closing at $9.30 per share on November 13, 2025.

Implications for Investors

For investors who feel they might have incurred losses due to these developments at Ardent, the class action lawsuit presents an opportunity to seek restitution. Those wishing to join the class are encouraged to express their interest before the deadline of March 9, 2026, which is the last day to apply for Lead Plaintiff status. Detailed information can be accessed through Pomerantz’s website.

About Pomerantz LLP

Pomerantz LLP is renowned for its specialization in corporate and securities class litigation, with a legacy spanning over 85 years. The firm was established by Abraham L. Pomerantz, a notable figure in class action law. Over the decades, it has recovered significant settlements for victims of corporate malfeasance and continues to stand as a beacon for shareholder rights in cases of alleged fraud and misconduct.

With offices in major cities including New York, Chicago, Los Angeles, and even international locations in London and Tel Aviv, Pomerantz has a robust reach in ensuring that investors are adequately represented in legal matters.

In conclusion, as Pomerantz LLP embarks on this significant legal challenge against Ardent Health, affected shareholders are reminded to act swiftly to safeguard their rights and interests. They can reach out to Danielle Peyton at Pomerantz LLP for further details on participating in the class action.